Hyperbolic Deprescribing: Pharmacokinetic Rationale and the 10% Rule
A technical evaluation of non-linear receptor occupancy curves, PET neuroimaging evidence, and the mathematical basis of exponential dose reduction for SSRIs, SNRIs, and antipsychotics.
Positron Emission Tomography (PET) neuroimaging demonstrates that drug-receptor binding follows a hyperbolic Michaelis-Menten relationship. At low milligram doses, the relationship between dose and receptor occupancy becomes extremely steep.
Consequently, conventional linear cuts (e.g. 50mg → 25mg → 0mg) cause catastrophic collapses in biological receptor buffering at the tail end. Tapering must proceed via exponential proportional decrements (the 10% Rule) to ensure linear receptor disengagement.
01 / Non-Linear Receptor Kinetics (The Michaelis-Menten Principle)
Receptor occupancy ($O$) as a function of drug concentration ($C$) follows the classic Hill equation:
Where $K_d$ represents the dissociation constant. This hyperbolic relationship dictates clinical tolerability:
- High Dose Saturation (Plateau): Increasing Citalopram from 20mg to 40mg increases SERT occupancy by only ~5% (from 80% to 85%). Conversely, dropping from 40mg to 20mg is easily tolerated.
- Low Dose Sensitivity (Steep Ascent): Dropping from 2.5mg Citalopram to 0mg strips away ~42% of biological receptor occupancy in a single day, throwing the central nervous system into acute crisis.
02 / Serotonin Transporter (SERT) PET Occupancy Ledger
PET radioligand studies (Meyer et al., Am J Psychiatry; Horowitz & Taylor, Lancet Psychiatry 2019) establish the following receptor dynamics:
| Citalopram Daily Dose | SERT Occupancy (%) | Biological Receptor Drop | Clinical Reaction |
|---|---|---|---|
| 20 mg | 80.0% | Baseline saturation | Steady state |
| 15 mg | 76.9% | −3.1% biological drop | Typically asymptomatic |
| 10 mg | 70.0% | −6.9% biological drop | Mild transient symptoms |
| 5 mg | 58.3% | −11.7% biological drop | Moderate receptor disengagement |
| 2.5 mg | 42.1% | −16.2% biological drop | Steep biological change |
| 1.25 mg | 27.3% | −14.8% biological drop | Micro-dosing required |
| 0.0 mg | 0.0% | −27.3% final drop | Tolerable only if tapered to <0.5mg |
03 / The 10% Exponential Decay Formulation
To maintain an approximately equal, linear decline in biological receptor occupancy, the milligram dose must be reduced exponentially:
Where $r$ represents the reduction rate (0.10 for 10%, or 0.05 for 5%), held across intervals of 2 to 4 weeks:
- Step 1 (Sertraline 50mg): 50mg − 10% (5.0mg) = 45.0 mg
- Step 2: 45mg − 10% (4.5mg) = 40.5 mg
- Step 3: 40.5mg − 10% (4.05mg) = 36.45 mg
- Step 10: ~17.4 mg
- Step 20: ~6.0 mg
- Step 30: ~2.1 mg
As the dose descends into the steep region of the curve, the milligram reductions become microscopic (e.g. 0.2mg cuts), keeping biological receptor change smooth and continuous.
04 / Antipsychotics & Dopamine D2 Supersensitivity
Horowitz et al. (Schizophrenia Bulletin 2021) demonstrated that dopamine D2 receptor blockade by antipsychotics (Quetiapine, Olanzapine, Risperidone, Aripiprazole) adheres to the exact same hyperbolic curve.
Chronic D2 antagonism induces homeostatic up-regulation of D2 receptor density—termed neuroleptic supersensitivity. Rapid reduction unleashes severe dopamine hypersensitivity, causing:
- Supersensitivity Psychosis: Rebound hallucinations or severe agitation that is qualitatively more intense than pre-treatment baseline.
- Histaminergic Rebound (Seroquel / Zyprexa): Antipsychotics with potent H1 histamine antagonism trigger acute insomnia, nausea, profuse sweating, and restlessness if withdrawn quickly.
Tapering must be conducted via hyperbolic decrements down to fractional doses (e.g. 0.5mg Quetiapine) before complete cessation.
05 / Clinical Formulation Mechanics: Achieving Micro-Doses
Commercial Oral Liquids
Prescribe licensed liquid solutions (e.g. Sertraline 20mg/mL, Escitalopram 1mg/mL, Fluoxetine 20mg/5mL). Measured with 1mL oral syringes in 0.01mL increments.
Compounding Pharmacies
Prescribe individualized liquid suspensions or precision capsules prepared by accredited compounding pharmacies in exact decimal milligram increments.
Capsule Bead Counting
For extended-release encapsulated pellets (Venlafaxine XR, Duloxetine), counting or weighing enteric beads on high-precision digital scales (0.001g).